Successful reversal of hepatic visceral crisis in HER2-positive metastatic breast cancer: a case report

1

Hepatic visceral crisis (HVC) in HER2-positive metastatic breast cancer is rare but presents significant management challenges.
2

A 51-year-old woman with severe hepatic dysfunction due to mBC-HER2+ achieved clinical improvement with trastuzumab and pertuzumab.
3

Initial treatment included dose-reduced paclitaxel, which was discontinued due to toxicity, while HER2 therapy continued uninterrupted.
4

The patient experienced normalization of liver function and a significant reduction in tumor marker levels after treatment.
5

This case highlights that early HER2-targeted therapy can lead to recovery in patients with HVC, bridging the evidence gap for high-risk groups.

Frontiers In Oncology

by Joan Manuel Moreno Luján, Jorge Luis Soriano Lorenzo, Miguel Martínez Rubiño, Sònia Servitja Tormo, Tamara Martos Cárdenas, María Martínez García, Joan Albanell Mestres
May 22, 2026

1